A substantial proportion of cancer-related mortality is attributable to recurrent, not de novo metastatic disease, yet we know relatively little about these patients. To fill this gap, investigators often use administrative codes for secondary malignant neoplasm or chemotherapy to identify recurrent cases in populationbased datasets. However, these algorithms have not been validated in large, contemporary, routine care cohorts.
C ancer is the second most common cause of death in the United States, accounting for approximately 600,000 lives lost per year. 1 Although some cancer deaths are attributable to progression of the primary disease, many, if not the majority, are due to recurrent metastatic cancer that develops among patients who previously completed definitive therapy and were declared disease free. 2 Patients with recurrent metastatic cancer may differ significantly from those with primary metastatic cancer, because they previously received cancer-directed therapy, have comorbid medical conditions from their prior disease or treatment, have a different distribution or extent of disease, or have different goals and values. Reliably identifying patients with recurrent cancer would facilitate efforts to compare the effectiveness of treatments given at the time of recurrence and would permit the use of recurrence-free survival as an outcome in comparative effectiveness research studies.
Tumor registries generate extensive information about patients with de novo metastatic disease, but they cannot do as much to illuminate the experiences of patients with recurrent metastatic disease because they do not have robust mechanisms for identifying recurrence. Some tumor registries, such as those available from Surveillance, Epidemiology and End Results (SEER) and the Cancer Research Network (CRN), have been linked with administrative data and used to assess cancer patients' patterns-of-care and outcomes. [3] [4] [5] [6] [7] [8] [9] Believing that these large, longitudinal, population-based datasets could also provide valuable information about recurrent cancer, investigators have developed algorithms that use the administrative codes for secondary malignant neoplasm and chemotherapy to identify patients with recurrent disease. Although a number of studies have used these codes to indicate which patients have recurrent cancer, [10] [11] [12] [13] few have assessed their validity as potential indicators of recurrence.
In a 2002 study of 89 acute myeloid leukemia patients treated at a large cancer center, Earle et al 14 assessed the ability of inpatient procedure codes for the administration of chemotherapy to identify relapse after a treatment gap of at least 4 months (N = 22 patients). The algorithm yielded a sensitivity of 86%, a specificity of 99%, and a PPV of 95%. In a study of 45 patients with node-positive breast cancer who received adjuvant chemotherapy as part of a clinical trial, Lamont et al 15 tested the ability of secondary malignant neoplasm codes to identify disease-free survival (N = 12 patients). At 5 years of follow-up, the algorithm yielded a sensitivity of 100% and a specificity of 97%, with an area under the receiver operator characteristic curve of 0.97.
Both studies relied on small, selected populations of patients with specific cancer types. The validity of secondary malignant neoplasm and chemotherapy codes in less selected cohorts and across multiple cancer types remains uncertain. Our goal was to test and validate these 2 previously published recurrence detection algorithms using 2 larger, more representative samples. Further evaluation of the methods currently being used to identify patients who have recurrent cancer is needed to ensure that our beliefs about this population are accurate. If administrative data fail to identify all patients who truly have recurrence or inappropriately classify patients as having recurrence, the resulting misclassification could lead to erroneous conclusions.
METHODS

Potential Indicators of Recurrence
The codes that we tested as potential indicators of cancer recurrence included the secondary malignant neoplasm codes described by Lamont et al 15 and the chemotherapy codes described by Earle et al. 14 The secondary malignant neoplasm codes included the International Classification of Diseases-Version 9-Clinical Modification (ICD-9-CM) diagnosis codes for disease involving specific organ sites (ie, 197-198.82 ). 15 As described by Lamont and colleagues, the code for secondary malignant neoplasm at the site of the original cancer was excluded as an indicator of recurrence [eg, when looking for recurrence after a lung cancer diagnosis, the code for secondary malignant neoplasm of the lung (197.0) was excluded], because we could not determine whether it referred to recurrent disease, the original caner, or a new primary. Also similar to the previous study, we conducted a sensitivity analysis in which we evaluated the impact of adding the secondary malignant neoplasm codes for lymph nodes and other nonspecific sites (ie, 196 and 198.89 ) to see if they improved sensitivity. The chemotherapy codes included generic codes for the administration of anticancer agents and specific codes for cytotoxic and targeted medications commonly used to treat cancer. Similar to the algorithm described by Earle et al, 14 we included ICD-9-CM, Current Procedure Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), Diagnosis-related Groups (DRG), revenue center, and Berenson-Eggers Type of Service (BETOS) codes (see Table, Supplemental Digital Content 1, http://links.lww.com/MLR/ A397 which provides a complete list of all codes used). To improve sensitivity, we added National Drug Codes (NDC); and to improve specificity we excluded hormonal therapy medications (because they are frequently used as part of prolonged adjuvant therapy or for nononcologic indications) and some chemotherapy medications that are rarely used to treat recurrent cancer (eg, topical 5-fluorouracil). To avoid the chance that chemotherapy given for adjuvant purposes would be construed as indicative of recurrence, we excluded chemotherapy occurring within 6 months of the index diagnosis for lung cancer and within 12 months for breast and colorectal cancer. These "blackout" periods were based on the duration of standard adjuvant chemotherapy regimens and a review of contemporary patterns-of-care. Finally, we assessed the performance characteristics of the 2 code-sets combined (ie, either secondary malignant neoplasm or chemotherapy codes).
Data Sources
We assessed the validity of these codes using 2 datasets that linked administrative codes, which provided potential indicators of recurrence, with information abstracted from the medical record, which provided gold-standard recurrence status. One dataset contained patients cared for in a fee-for-service setting (CanCORS/Medicare) and the other contained patients cared for in a health maintenance organization-based Cancer Research Network (HMO/CRN). We hypothesized that a code-based algorithm would be a more sensitive indicator of recurrence when applied to the fee-forservice versus the capitation environment.
CanCORS/Medicare
The Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium is a large, prospective, population and health system-based study of the care provided to and outcomes experienced by patients from across the United States with lung and colorectal cancer diagnosed during [2003] [2004] [2005] . The CanCORS dataset includes information from surveys of patients or their surrogates, and from the abstraction of patients' medical records. Details of the study design, population, and data collection procedures have been described elsewhere. 16 
HMO/CRN
The CRN is a consortium of 14 health care organizations affiliated with the HMO Research Network and the National Cancer Institute (http://crn.cancer.gov/). The CRN's Virtual Data Warehouse (VDW) was the primary data source for this analysis. Described in detail elsewhere, 17, 18 the VDW is a distributed data system using standard data formats and definitions where each HMO retains local control of its data, but a central programmer can direct extraction and analysis of data across all participating sites. It includes data on patient demographics, health plan enrollment, SEER-compatible tumor characteristics, and cancer treatments. For this analysis, we used data from the 2 HMO/CRN sites that have "in-house" tumor registries staffed by certified tumor registrars who collect high-quality data regarding recurrence status. Both sites, Kaiser Permanente Colorado, Denver, CO and Kaiser Permanente Northwest, Portland, OR, provide comprehensive health services through closed panel delivery models with salaried physicians. Institutional review boards from both participating CRN sites approved this project.
Study Populations and Data Extraction
For both datasets we identified patients with newly diagnosed stage I-III lung, colorectal, breast, and prostate cancer. Patients with locally advanced or primarily progressive disease and those who did not complete definitive local-regional therapy were excluded, because we wanted to focus on patients for whom recurrence detection would be relatively easy (ie, we only wanted to test the validity of these codes in situations that maximized their potential sensitivity and specificity). Therefore, patients with stage IIIb lung cancer, those who did not have definitive localregional therapy within 12 months of their index cancer diagnosis, and those who were never noted to be disease-free were excluded. Patients who were missing medical record abstraction data, those who had unknown recurrence status, and those who had documentation of recurrent disease in the medical record before they had definitive local therapy were also excluded. Patients with no documented recurrence who died from causes other than cancer were considered nonrecurrent.
For the CanCORS/Medicare sample, patients had to be continuously enrolled in Medicare Parts A & B from the month of cancer diagnosis to 18 months later or death (whichever came first), where continuous enrollment was defined as no more than 2 consecutive months without enrollment. Patients enrolled in Medicare Advantage plans were excluded out of concern that their claims data were incomplete. Patients had to have at least 1 Medicare claim to ensure they were seeking care for their index cancer. Medical record abstraction data were used to characterize patients' gold-standard recurrence status. The suggestion of recurrence in a radiology report, without confirmation in a clinician's note, was not considered sufficient to indicate recurrence. Characteristics of the patients (eg, age, race/ ethnicity, education, income, comorbid diagnoses, 19, 20 etc.) and their diagnoses (eg, stage, grade, etc.) were derived from the medical record abstraction and patient/surrogate survey files. Administrative codes were extracted from the Medicare hospital (MedPAR), physician (Carrier), and Outpatient facility claims files (Note: NDC codes were not available from the Medicare files during the years encompassed by this analysis). To assign a date to each Medicare code the "claim through date" was used for all files except MedPAR where the discharge date was used.
The HMO/CRN database, unlike CanCORs/Medicare, continuously enrolls patients. For this analysis, the HMO/CRN cohort included incident cancer cases diagnosed between January 1, 2000 and December 31, 2005. Cases were linked to enrollment, census, pharmacy, procedure, and diagnosis data from 12 months before the incident cancer diagnosis until death, disenrollment, or the end of the study period (December 31, 2008). Gold-standard recurrence status was ascertained by tumor registrars during routine chart surveillance efforts. Characteristics of the patients and their diagnoses were ascertained using the VDW tumor registry, census, pharmacy, procedure, and diagnosis databases. The majority of the HMO/ CRN encounter codes were derived from events documented in KP HealthConnect (an EpicCare-based electronic medical record); a smaller proportion (< 15%) were identified using claims data when services were delivered by contract providers. Health care event-specific data were extracted from the VDW files. Like CanCORS/Medicare, this included ICD-9, CPT, HCPCS, and DRG codes; whereas revenue center and BETOS codes were not available for HMO/CRN patients, NDC codes were. Depending on the data source, the "procedure date," "encounter date," or "dispense date" was used to assign a time to each code.
Analysis
To evaluate the validity of these administrative codes as indicators of recurrence, we calculated their sensitivity and specificity. For the CanCORS/Medicare cohort, we assessed recurrence 14 months after the index cancer diagnosis because the CanCORS chart abstraction process (which provided the gold-standard recurrence status) was designed to capture medical records up to 15 months postdiagnosis. Longer follow-up was available for the HMO/CRN cohort, so for these patients we assessed recurrence at both 14 and 60 months. For each time point, the cohort included patients who were followed for at least that number of months as well as any patients who developed recurrence or died before that time regardless the duration of follow-up. A patient was classified as having an indicator of recurrence if at least 1 relevant code was present on or before the final month of the assessment period.
We also used the HMO/CRN cohort to calculate the positive predictive value (PPV), defined as the proportion of patients who had recurrence among those who had codes indicative of recurrence. The PPV analysis was done only for the HMO/CRN cohort, because the CanCORS/Medicare cohort was smaller and the selective censoring of nonrecurrent cases suggested that the 14-month CanCORS/ Medicare sample might not be representative of the broader population. We explored trends in sensitivity, specificity, and PPV across the different data sources, cancer types, stages, and time points.
RESULTS
We identified 929 CanCORS/Medicare and 5298 HMO/ CRN patents, all of whom received definitive local therapy for stage I-III lung, colon, breast, or prostate cancer and had administrative data linked to gold-standard recurrence status. Major reasons for exclusion included having stage IV disease, not having definitive local therapy within 12 months, and, among CanCORS/Medicare patients, being enrolled in a managed care organization ( Table 1 ). There were 115 confirmed recurrences in the CanCORS/Medicare cohort and 621 confirmed recurrences in the HMO/CRN cohort. Compared with CanCORS/Medicare patients, HMO/CRN patients had greater cumulative recurrence rates consistent with their longer median follow-up (14 mo for CanCORS/Medicare vs. 60 mo for HMO/CRN). Not surprisingly, the CanCORS/ Medicare cohort contained a smaller proportion of patients younger than 65 years, and a larger proportion of patients who were non-Hispanic black, had less than a high school education, had an estimated annual income of <$20,000, and had a higher comorbidity index ( Table 2) .
Among patients with lung, colorectal, and breast cancer, the combination of secondary malignancy and chemotherapy codes consistently offered the highest sensitivity; chemotherapy codes alone offered the lowest sensitivity and secondary malignancy codes alone were the most specific (Table 3) . No 1 set of codes consistently demonstrated both the highest sensitivity and the highest specificity. For patients with prostate cancer, none of the code-sets offered a sensitivity >19% and all of the code-sets offered a specificity >83%. Comparing the pattern and magnitude of results for the 14 versus 60-month time points and for the CanCORS/ Medicare versus HMO/CRN datasets, the findings did not seem to change substantially. For patients with lung, colorectal, and breast cancer, adding the ICD-9 codes for secondary malignant neoplasm involving lymph nodes and other nonspecific sites (ie, 196; 198 .89) to the core set of secondary malignant neoplasm codes increased sensitivity, but decreased specificity (Fig. 1A) . When the results for the combination of secondary malignancy and chemotherapy codes were stratified by stage at diagnosis, we found that as stage increased the sensitivity increased and the specificity decreased (Fig. 1B) .
Not surprisingly, among lung, colorectal, and breast cancer patients from the HMO/CRN cohort, the most specific code-set generated the highest PPVs (94%, 94%, and 87%, respectively for secondary malignancy codes at 60 mo) (Fig. 2) . The most sensitive code-set, the combination of secondary malignancy and chemotherapy codes, yielded PPVs of 72% for lung cancer, 53% for colorectal cancer, and 30% for breast cancer. The PPV tended to be higher when recurrence was more prevalent [ie, lung vs. colorectal or breast cancer; 60 vs. 14 mo analysis; stage III vs. stage I at diagnosis (stage-specific PPVs not shown)]. No code-set offered a PPV > 31% for prostate cancer.
CONCLUSIONS
We performed a validation study of secondary malignant neoplasm and chemotherapy codes as potential indicators of recurrence for patients with lung, colorectal, breast, and prostate cancer. Excluding patients who did *Patients were excluded because they had unknown recurrence status after definitive local therapy, were noted to have had a recurrence before definitive local therapy, or were last noted to be recurrence-free before definitive local therapy. not complete definitive local therapy or who had primary progressive disease allowed us to focus on patients for whom we thought recurrence detection would be less challenging. Even so, for patients with lung, colorectal, and breast cancer secondary malignancy codes offered a sensitivity of only 56%-74% and chemotherapy codes offered a sensitivity of only 28%-62% across different time-points and datasets. The combination of secondary malignant neoplasm or chemotherapy codes yielded more desirable sensitivities (75%-85%) and specificities (70%-88%), but there was still room -15  16  16  16  2001  --15  16  17  18  2002  --18  16  18  20  2003  26  29  16  16  17  18  2004  67  68  19  18  16  17  2005  7  3  17  17  17  12  Stage  I  7 2  3 1  5 9  3 0  5 8  1  II  17  36  17  38  34  89  III  11  33  24  32  8  11 *The vast majority of patients with breast cancer (> 99%) were female, but a small number were male. The proportions of men and women with breast cancer were not reported to comply with the terms of the data use agreement stating that cells with r10 patients not be reported. The proportions were noted as NR, indicating that the values were not reported. z Education data for the HMO/CRN cohort were obtained from block-level Census data; the results represent the mean proportion of people who attained each level of education across the census tracts in which the patients actually resided. The results are in parentheses to highlight this difference.
y Income data for the HMO/CRN cohort were obtained from block-level Census data. The results are in parentheses to highlight this difference. 8 Comorbidity index derived using methods developed by Charlson and colleagues, 19, 20 excluding cancer diagnoses.
for improvement. No code-set detected recurrent prostate cancer reliably. To our surprise, there was no consistent difference in the results from the fee-for-service environment of Medicare compared with the capitation environment of the CRN. There are several reasons why our findings may differ from those published previously. It is not surprising that chemotherapy codes were better at identifying patients who received reinduction chemotherapy for AML compared with patients with recurrent solid organ malignancies. 14 Many patients with recurrent lung, colorectal, breast, and prostate cancer do not receive chemotherapy at the time of recurrence; some are treated with another modality of therapy (eg, hormonal therapy, radiation therapy, surgery, etc.) and others receive no cancer-directed therapy at all. Our cohort differed substantially from that described by Lamont et al, 15 which only included patients with node-positive breast cancer who were 65 years and older and had participated in a clinical trial. Even when we restricted our analysis to patients with stage II-III breast cancer, the secondary malignant neoplasm codes still seemed to be less sensitive (65%-78%) than previously reported. Documentation of the administrative codes used as potential indicators of recurrence may have been more likely among clinical trial participants, patients receiving care at institutions that offer clinical trials, those who were 65 years and older, or those who were treated in the more distant past. Several studies have assessed the ability of administrative codes to identify patients who developed either recurrent or second primary cancer. 21, 22 Although these studies reported sensitivities and specificities that were high, the use of a combined outcome (ie, recurrence or second primary cancer) makes it hard to assess how well these algorithms would detect recurrence alone.
Our analysis highlights a number of challenges with identifying patients who have recurrent cancer. First, secondary malignant neoplasm and chemotherapy codes alone offered disappointingly low sensitivities. To improve sensitivity, it may be necessary to add additional indicators, such as imaging, radiation therapy, hormonal therapy, or hospice codes. Some codes, such as those for imaging and hospice, could be particularly helpful at identifying patients who receive no cancer-directed therapy at the time of recurrence. Second, in light of the observation that cancer type affected the performance characteristics of billing/encounter codes, developing 1 recurrence detection algorithm that works for all cancer types may be impractical. An alternate approach would be to start with an all-encompassing list of codes for common solid organ cancers, and selectively exclude those that reduce specificity and do not increase sensitivity on a cancer-by-cancer basis. Third, identifying patients who have recurrent disease is not enough; it is also important to characterize the time when recurrence occurs. Finally, it is hard to identify a specific threshold for sensitivity and specificity that should be considered good enough. The optimal threshold may depend on the goal of the analysis, including whether it is more important to optimize sensitivity or specificity. If used alone, an algorithm with a low PPV could result in misclassification such that efforts to make comparisons across groups would yield biased estimates of statistical parameters such as odds ratios. The secondary malignancy codes include ICD-9 codes for secondary malignant neoplasm associated with a solid organ. z The chemotherapy codes include procedure codes for the administration of chemotherapy agents and medication codes for specific chemotherapy drugs. ICD-9, DRG, CPT, and HCPC codes were used for both datasets; revenue center and BETOS were also used for CanCORS/Medicare patients; NDC codes were also used for HMO/CRN patients.
y Either: secondary malignancy or chemotherapy codes.
Our results are limited by the potential for inaccuracies when classifying patients' gold-standard recurrence status. Given the stringent definitions used to identify gold-standard recurrence status, the risk of inappropriately classifying patients as nonrecurrent according to the gold-standard is greater than the risk of inappropriately classifying patients as recurrent. Findings from the CanCORS/Medicare cohort are limited by relatively short follow-up; however, it was reassuring that the 14 and 60-month findings from the HMO/ CRN cohort were similar. Some of the codes used to indicate recurrence can also be used to document initial cancer care (eg, adjuvant chemotherapy, regional lymph node involvement, etc.). We tried to address this issue by excluding chemotherapy codes that occurred within 6 months after a lung cancer diagnosis or within 12 months after a colorectal/ breast cancer diagnosis; the optimal "black-out" window is unknown. Unlike one of the original studies, 15 we assessed the performance of administrative codes as indicators of recurrence alone, not recurrence or death. Given the small number of deaths in our cohort and the pattern of code documentation, changing the outcome to include death would likely have had either no impact or a negative effect on sensitivity and specificity. The large sample size, different cancer types, and various practice settings included in our analysis are important strengths.
Investigators who use secondary malignant neoplasm or chemotherapy codes to identify cancer recurrence should be aware of their potential for misclassification. The optimal thresholds for sensitivity and specificity can be determined only by investigators in consideration of their individual research goals, but there does seem to be room to improve the performance of currently available recurrence detection methods. Although secondary malignant neoplasm and chemotherapy codes may be suboptimal for some investigators, they do offer potential and could serve as the foundation for a more sophisticated recurrence algorithm that incorporates additional indicators and accounts for the primary cancer type. 23 Rather than providing an absolute characterization of recurrence status (yes vs. no), it could be more useful to develop a flexible tool that generates a probability of having recurrence in a defined time period. Continued efforts to develop an algorithm that identifies recurrent cancer using administrative data are worthwhile, because although success may not be assured the alternative, asking registries to track recurrence status, would likely be cost prohibitive. A well-validated, claims-based algorithm could provide valuable information about the experiences and outcomes of the many patients with recurrent cancer and help realize the full potential of administrative databases for comparative effectiveness research. 14 mo. 60 mo.
